GMA
Both doses reduced Menopause Rating Scale scores versus placebo; signals were also reported for hot flashes, sleep, mood and anxiety.
The multicentre randomised double-blind placebo-controlled study included 150 women aged 40–60. Participants received 300 mg or 500 mg of Fenavari®, a standardised combination of Trigonella foenum-graecum and Asparagus racemosus, or placebo for 84 days.
Both doses improved total Menopause Rating Scale scores versus placebo, with a larger effect at 500 mg. Authors also report favourable results for hot flashes, night sweats, sleep, mood and anxiety.
The study is peer-reviewed, but one author is employed by OmniActive Health Technologies. Its duration is short and several outcomes are subjective: the dossier becomes more substantial, but still needs independent confirmation and longer follow-up.
The study illustrates branded-botanical development through standardisation, dose response and multiple outcomes in a fast-growing women’s-health category.
A short study connected to the ingredient manufacturer. Independent replication, longer follow-up and caution in transferring findings to other extracts are required.
Editorial note. This content is intended for industry professionals. It does not constitute medical advice, therapeutic guidance or regulatory advice. Read our editorial method.
Read the original source · Women’s Health Reports / PubMed